



Ref. No.: EIKO/BSE/2023-24/36

Date: 08th November 2023

To,
Corporate Services Department,
BSE Limited,
P J Towers,
1st Floor, Dalal Street,
Fort, Mumbai - 400001.

Scrip Code: 540204

Sub: Outcome of the Board Meeting

Dear Sir,

Pursuant to Regulation 30 and 33 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), we would like to inform you that the Board of Directors in their meeting held today i.e., 08th November, 2023 inter-alia, approved the following matters:

1. Considered and approved the Un-audited Financial Results of the Company for the quarter and half year ended on 30th September, 2023 along with the Limited review Report given by Statutory Auditor of the Company (**Annexure - A**).
2. Appointment of Mr. Chintan B. Doshi (ICSI Membership No. ACS 36190) as a "Company Secretary and Compliance Officer" pursuant to section 203 of the Companies Act, 2013 and Regulation 6(1) of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 with immediate effect.

*The requisite disclosure under regulation 30 of SEBI (LODR), Regulation 2015 read with Circular No. CIR/CIR/CFD/CMD/4/2015 dated September 9, 2015, and SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 is enclosed as (**Annexure-B**)*

The Meeting was commenced at 6.00 PM and concluded at 6.45 PM.

For Eiko Lifesciences Limited

Laxmikant Kabra

Chairman and Non-Executive Director



Independent Auditor's Review Report on the Quarterly and Half Year Ended Unaudited Financial Results of the Company Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To the Board of Directors
Eiko Lifesciences Limited
(Formerly known as Narendra Investments (Delhi) Limited)

1. We have reviewed the accompanying statement of Unaudited Financial Results of **Eiko Lifesciences Limited** (Formerly known as Narendra Investments (Delhi) Limited) (the "Company") for the quarter and half year ended September 30, 2023 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial result prepared in accordance with applicable Principles laid down in Indian Accounting Standards 34 "Interim Financial Reporting" ("Ind AS 34") prescribed under section 133 of companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015 read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement

For Thanawala & Company
Chartered Accountants
Firm Reg. No.: 110948W

CA Vijay Thanawala
Proprietor
Membership No.: 015632



Place: Thane
Date: 8th November 2023

UDIN: 23015632BGWOKN5834

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30th SEPTEMBER 2023

(₹ in Lakhs except EPS)

Sr. No.	Particulars	Quarter ended			Half year ended		Year ended
		30.09.2023	30.06.2023	30.09.2022	30.09.2023	30.09.2022	31-03-2023
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Revenue from operations	641.27	650.78	431.05	1,292.05	735.12	1,832.14
	Other income	2.81	2.72	22.57	5.54	46.07	85.48
	Total revenue	644.09	653.50	453.62	1,297.59	781.19	1,917.62
2	Expenses						
	Cost of Material consumed	660.21	603.55	330.41	1,263.76	540.03	1,366.49
	Changes in inventories of finished stock and work-in-progress	(89.26)	(0.44)	56.24	(89.71)	91.98	242.85
	Employee benefits expense	4.95	5.34	6.78	10.29	14.52	28.71
	Depreciation and amortization expense	16.06	16.05	15.77	32.11	31.50	63.28
	Finance Cost	6.10	3.37	1.49	9.47	10.26	15.03
	Other expenses	29.86	14.78	23.11	44.64	61.99	98.64
	Total expenses	627.93	642.63	433.79	1,270.56	750.29	1,815.00
3	Profit/(Loss) from ordinary activities before tax	16.16	10.87	19.83	27.03	30.90	102.62
4	Tax expense:						
	(1) Current tax	-	-	-	-	-	4.84
	(2) Deferred tax	4.07	2.86	4.92	6.93	7.70	20.91
5	Profit/(Loss) from ordinary activities after tax	12.09	8.00	14.91	20.10	23.19	76.88
6	Other Comprehensive Income (OCI)						
	<u>Item that will not be reclassified to profit or loss</u>						
	Gain/(Loss) on recognised on fair valuation of Financial Assets	-	-	4.21	-	3.21	3.21
	Income tax relating to these items	-	-	(1.06)	-	(0.81)	(0.81)
	Total Other Comprehensive Income (OCI)	-	-	3.15	-	2.40	2.40
	Profit/(Loss) for the Period	12.09	8.00	18.07	20.10	25.59	79.28
7	Paid up Equity Share Capital (Face Value of Rs. 10 each)	997.95	831.63	831.63	831.63	831.63	831.63
	Earnings Per Share (EPS) (Not annualised)						
	(1) Basic	0.12	0.08	0.15	0.20	0.24	0.79
	(2) Diluted	0.12	0.08	0.15	0.20	0.24	0.79



Notes:


1. The above Financial Results for the quarter and half year ended 30th September 2023 have been reviewed and recommended by Audit Committee and has been approved by the Board of Directors at its Meeting held on Wednesday, 8th November 2023. The Statutory Auditors have carried out Limited Review of above results and expressed an unmodified opinion on these financial results.
2. The Company has single business segment namely "Speciality & Fine Chemicals" therefore in the context of Ind As 108, disclosure of segment information is not applicable.
3. The Company issued 55,44,178 equity shares of face value of ₹ 10/- each ('Rights Equity Shares') to the Eligible Equity Shareholders at an issue price of ₹45 per Rights Equity Share (including premium of ₹ 35 per Rights Equity Share). The Rights Equity Shares were issued as partly paid-up and an amount of ₹13.50 per Rights Equity Share was payable on application (of which ₹ 3 towards face value of Rights Equity Share and ₹ 10.5 towards premium amount of Rights Equity Share). Balance to be payable in one or more call. There is no deviation in use of proceeds from the objects stated in the Offer document for rights issue.

Pursuant to IND AS 33, basic and diluted earnings per share for the previous periods have been restated for the bonus element in respect of right issue made during the quarter ended 30th September 2023.
4. Other Expenses of quarter and half year ended 30.09.2023 includes expenses incurred on account of issue of Equity Shares on rights basis amounting to ₹19.68 Lakhs.
5. Previous quarter figures have been regrouped reclassified wherever necessary, to make them comparable.

For Eiko Lifesciences Limited

L.K. Kabra

Laxmikant Kabra
Chairman
DIN: 00061346




Place: Thane
Date: 8th November 2023

Disclosure of Assets and Liabilities as per Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as of 30th September 2023

(₹ in Lakhs)

Particulars	As of 30-09-2023	As of 31-03-2023
ASSETS		
Non-current assets		
Property, Plant and Equipment	1,360.70	1,388.11
<u>Financial Assets</u>		
Investments	406.85	5.35
Loans	177.66	668.44
Other Financial Assets	-	-
Deferred Tax Asset	-	-
	1,945.21	2,061.90
Current assets		
Inventories	133.24	90.76
<u>Financial Assets</u>		
Trade Receivables	1,009.99	710.56
Cash and cash equivalents	495.04	173.50
Other Current Financial Assets	-	-
Other Current Assets	406.23	67.56
	2,044.49	1,042.38
TOTAL ASSET	3,989.70	3,104.28
EQUITY AND LIABILITIES		
EQUITY		
Equity Share capital	997.95	831.63
Other Equity	2,712.84	2,110.60
Share Application Money Pending for Allotment	-	-
	3,710.79	2,942.23
LIABILITIES		
Non-current liabilities		
<u>Financial Liabilities</u>		
Non-Current Borrowings	-	-
Deferred Tax Liabilities	49.11	42.18
	49.11	42.18
Current liabilities		
<u>Financial Liabilities</u>		
Current Borrowing	86.02	-
Trade payables	135.32	104.53
Other financial liabilities	1.37	5.36
Current Tax Liabilities	-	-
Provisions	1.50	4.55
Other current Liability	5.59	5.43
	229.80	119.87
TOTAL LIABILITIES	3,989.70	3,104.28

L.K. Sabus




Disclosure of cashflow as per Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for 30th September 2023

(₹ in Lakhs)

Particulars	Period Ended 30.09.2023	Year ended 31.03.2023
A. CASH FLOW FROM OPERATING ACTIVITIES		
Net (loss) / profit before tax	27.03	102.62
Adjustments for		
Depreciation and Amortisation Expense	32.11	63.28
Interest Income classified as investing cash flow	(5.51)	(72.71)
Profit on Sales of Investments	-	(3.15)
Finance Costs	9.47	15.03
Dividend Income	(0.03)	(0.00)
Operating profit before working capital changes	63.07	105.07
Working capital adjustments: -		
Increase / (Decrease) in Trade and Other Payables	30.79	(30.31)
Increase / (Decrease) in Provisions	(3.04)	1.20
Increase / (Decrease) in Other Financial Liabilities	(3.99)	(2.09)
Increase / (Decrease) in Other Current Liabilities	0.16	0.44
(Increase) / Decrease in Inventories	(42.48)	454.99
(Increase) / Decrease in Trade Receivables	(299.43)	(254.33)
(Increase) / Decrease in Other Current Assets	(338.67)	139.88
Cash generated from / (used in) operations	(593.59)	414.85
Direct taxes paid (Net of Refunds)	-	7.53
Net cash (used in) / from generated from operating activities	(593.59)	422.38
B. CASH FLOW FROM INVESTING ACTIVITIES		
Sale/(Purchase) of Investments	(401.50)	21.02
Sale/(Purchase) of Fixed Assets	(4.70)	(22.47)
Proceed from Deposit	490.78	128.47
Interest Income	5.51	72.71
Dividend received	0.03	0.00
Net cash (used in) / generated from investing activities	90.12	199.73
C. CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds from issue of shares	748.46	-
Interest paid	(9.47)	(15.03)
Proceeds /(Repayment) from borrowings	86.02	(455.32)
Net cash (used in) / from financing activities	825.01	(470.35)
Net Increase in cash and cash equivalents (A+B+C)	321.54	151.77
Cash and cash equivalents at the beginning of the year	173.50	21.73
Cash and cash equivalents at the end of the year	495.04	173.50

L.K. Sabnis



**Annexure-B**

Disclosures as required under Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Appointment of Mr. Chintan B. Joshi as the Company Secretary & Compliance officer of the Company.

Sr No	Particulars	Details
1.	Reason for change viz. appointment	Appointment as Company Secretary & Compliance Officer of the Company
2.	Date of appointment	08 th November, 2023
3.	Name of KMP	Chintan B. Doshi
4.	Designation	Company Secretary
5.	Membership Number	ACS 36190
6.	Education Qualification	Company Secretary (ICSI)
7.	Brief profile (in case of appointment)	Qualified Company Secretary
8.	Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable
9.	Shareholding in the Company	Nil

For Eiko Lifesciences Limited**Laxmikant Kabra**

Chairman and Non-Executive Director